Tiuxetan

 
National Institutes of Health

Topic mentions per year

Topic mentions per year

2001-2017
012320012017

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2015
2015
PURPOSE The main drawbacks of radioimmunotherapy have been severe hematological toxicity and potential development of… (More)
Is this relevant?
2015
2014
2012
2012
AIM The aim of this study was to compare different dosimetric approaches on therapy naïve patients enrolled in a multicentre… (More)
Is this relevant?
2011
2011
BACKGROUND This retrospective analysis is focused on the efficacy and safety of radioimmunotherapy (RIT) with Zevalin® in nine… (More)
  • figure 1
  • table 1
  • table 2
Is this relevant?
2009
2009
PURPOSE The randomized First-Line Indolent Trial (FIT) was conducted in patients with advanced follicular lymphoma (FL), to… (More)
Is this relevant?
2008
2008
90Yttrium-ibritumomab-tiuxetan (Zevalin) is an effective treatment for relapsed or refractory low-grade, follicular, or… (More)
  • table 1
  • table 2
  • figure 1
  • figure 2
  • figure 3
Is this relevant?
Review
2005
Review
2005
Radioimmunotherapy (RIT) is among the newest modalities for treating the diverse neoplasms known as non-Hodgkin lymphomas (NHLs… (More)
  • table I
  • figure 1
  • figure 2
  • table II
  • table III
Is this relevant?
Review
2004
Review
2004
This article will review the clinical development of ibritumomab tiuxetan, a yttrium-90-conjugated monoclonal antibody to CD20… (More)
Is this relevant?
Review
2002
Review
2002
The clinical development and US Food and Drug Administration approval in 1997 of the monoclonal anti-CD20 antibody rituximab have… (More)
Is this relevant?